Skip to content

Effect of Combined Acetaminophen/Ibuprofen Injection on Postoperative Pain Reduction and Opioid Consumption in Patients Undergoing Video-assisted Thoracoscopic lung Resection; ACEIBU trial

Effect of Combined Acetaminophen/Ibuprofen Injection on Postoperative Pain Reduction and Opioid Consumption in Patients Undergoing Video-assisted Thoracoscopic lung Resection; ACEIBU trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0012021
Enrollment
158
Registered
2026-05-21
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Experimental group: Acetaminophen 1000mg + Ibuprofen 300mg injectable combination (Maxigesic Inj. 100ml, 1 vial) is administered intravenously every 6 hours for 8 doses. This medication is give

Sponsors

Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - men and women over 19 years of age - a patient scheduled for thoracoscopic lung resection

Exclusion criteria

Exclusion criteria: - Women who are pregnant or lactating, women who plan to become pregnant during clinical trials - a patient on anti-inflammatory medication for chronic inflammatory disease - an active alcoholic patient - Patients with a history of hypersensitivity or history of nonsteroidal anti-inflammatory drugs - a patient with a severe liver disorder - Patients with gastrointestinal ulcers, gastrointestinal bleeding, or a history of it - a patient with bronchial asthma or a history of it - Other conditions/abnormalities: uncontrolled or uncontrolled medical endocrine or uncontrolled hematologic abnormalities among clinically significant cardiovascular, neurological, psychiatric, kidney, liver, immunity, medication carefully administered (including those in this condition; coronary artery disease, acute myocardial infarction, deep vein thrombosis, hypertension, convulsive disorder, thyrotoxicosis, hypokalemia, etc.) - a weight of less than 50 kg * Significance is defined as any disease that will affect the efficacy or safety analysis if, as judged by the clinical trial physician, the safety of the subject is put at risk by participation or if the condition/condition deteriorates during the clinical trial

Design outcomes

Primary

MeasureTime frame
Maximum pain score within 48 hours after surgery

Secondary

MeasureTime frame
Vital signs and blood test results;Pain Score (NRS);opioid dugs dosage;a combination of drugs;adverse event(AE)

Countries

Korea, Republic of

Contacts

Public ContactDa-yi Jung

Samsung Medical Center

joungdayi@naver.com+82-2-2148-7380

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: May 30, 2026